Core Viewpoint - The company Jianbei Miao Miao (02161) reported a strong performance in its interim results, leading to a significant increase in its stock price by over 5% [1] Financial Performance - The company reported revenue of approximately HKD 430 million for the six months ending September 30, 2025, representing a year-on-year increase of about 7.7% [1] - The profit attributable to equity holders was approximately HKD 115 million, reflecting a year-on-year increase of about 20.0% [1] - Earnings per share were reported at 14.12 HKD cents, with an interim dividend of 9.75 HKD cents per ordinary share [1] Business Segments - The growth in performance was primarily driven by strong sales from core brands, particularly in the branded pharmaceuticals segment with He Ji Gong and the traditional Chinese medicine segment with Bao Ji Wan [1] - The company's focus on brand management and effective market promotion execution contributed to the positive sales performance [1] - The traditional Chinese medicine formula granules business also showed stable performance, providing continuous contributions to the health business group [1]

Core Viewpoint - The company Jianbei Miaomiao (02161) reported a strong performance in its interim results, leading to a significant increase in its stock price by over 5% [1] Financial Performance - The company reported revenue of approximately HKD 430 million for the six months ending September 30, 2025, representing a year-on-year increase of about 7.7% [1] - The profit attributable to equity holders was approximately HKD 115 million, reflecting a year-on-year increase of about 20.0% [1] - Earnings per share were reported at 14.12 HKD cents, with an interim dividend of 9.75 HKD cents per ordinary share [1] Business Segments - The growth in performance was primarily driven by strong sales from core brands, particularly the branded pharmaceutical segment's He Jigong and the traditional Chinese medicine segment's Baoji Wan [1] - The company attributed its success to focused brand management and effective market promotion execution [1] - The traditional Chinese medicine formula granules business also showed stable performance, contributing consistently to the overall health business group [1]

Core Viewpoint - The company reported a revenue of approximately HKD 430 million for the six months ending September 30, 2025, representing a year-on-year increase of about 7.7% [1] - Profit attributable to equity holders was approximately HKD 115 million, reflecting a year-on-year increase of about 20.0% [1] - The earnings per share were HKD 0.1412, with an interim dividend of HKD 0.0975 per ordinary share [1] Revenue Performance - The revenue growth was primarily driven by strong sales performance of core brands, particularly the branded pharmaceutical segment's He Ji Gong and the traditional Chinese medicine segment's Bao Ji Wan [1] - Focused brand management and effective market promotion execution contributed to the sales performance [1] Business Segments - The Chinese medicine formula granules business showed stable performance, continuously contributing to the brand health business group [1]

Core Viewpoint - The company reported a strong performance in its interim results for the six months ending September 30, 2025, with significant growth in revenue and profit driven by robust sales of its core brands [1] Financial Performance - Revenue reached approximately HKD 430 million, representing a year-on-year increase of about 7.7% [1] - Profit attributable to equity holders was approximately HKD 115 million, reflecting a year-on-year increase of about 20.0% [1] - Earnings per share were HKD 0.1412, with an interim dividend of HKD 0.0975 per ordinary share [1] Business Segments - The growth in performance was primarily attributed to strong sales in the branded pharmaceutical segment, particularly the He Ji Gong brand, and the traditional Chinese medicine segment, especially the Bao Ji Wan product [1] - The company emphasized effective brand management and successful market promotion as key factors in driving sales [1] - The traditional Chinese medicine formula granules business also showed stable performance, contributing consistently to the overall health business group [1]

Core Viewpoint - The article highlights significant movements in the Hong Kong and US stock markets, driven by geopolitical tensions, corporate earnings, and strategic partnerships, indicating potential investment opportunities and sector performance trends. Group 1: Hong Kong Stock Market Highlights - Gold stocks opened high due to rising geopolitical tensions in the Middle East, with gold prices surpassing $3,400 [1] - Chow Tai Fook (01929) rose over 7% post-earnings, with Morgan Stanley raising its target price by 7.7% to HKD 14, reflecting better-than-expected fiscal 2025 results and a continued demand recovery [1] - Eucure Biopharma-B (01477) increased over 6% after receiving approval for its OT-802 Phase III clinical trial in China [1] - Television Broadcasts (00511) surged over 12% following partnership agreements with Tencent Video, Shenzhen Satellite TV, Huawei, and iFlytek [1] - Four Seasons Pharmaceutical (00460) rose over 4% as its new drug application for Pyrotinib was officially accepted by NMPA [1] - Jianbei Miao Miao (02161) increased over 6% with a 51.2% year-on-year growth in net profit, attributed to strong performance from flagship brands [1] - ConvaTec-B (02162) fell over 6% due to a discounted share placement raising over HKD 850 million, with the controlling shareholder reducing their stake [1] Group 2: Sector Performance and Trends - Shipping stocks rose against the trend, with Cosco Shipping Energy (01138) up over 10%, influenced by ongoing geopolitical crises affecting the Red Sea [2] - Automotive stocks declined across the board, with Xpeng Motors dropping over 5% amid potential tariff increases on vehicles [2] - Shandong Molong (00568) surged over 60% as oil prices spiked over 10% due to heightened geopolitical risks [2] - Innovative drug concept stocks faced significant declines, with several biotech companies experiencing a wave of share placements [2] - North Sea Kangcheng-B (01228) rose over 31% after receiving approval for its injectable drug [2] - Delin International (01126) increased over 10%, with positive outlooks for the toy market [2] Group 3: US Stock Market Highlights - Boeing (BA.US) fell 4.81% following the first accident involving its 787 aircraft [3] - CureVac (CVAC.US) surged over 37% after BioNTech announced a $1.25 billion acquisition to enhance its cancer business [3] - Oracle (ORCL.US) rose 13.25% as it projected over 70% growth in cloud infrastructure sales [3] - Adobe (ADBE.US) initially rose over 6% but later fell over 1%, reporting Q2 revenue of $5.87 billion, exceeding analyst expectations [3] - MP Materials (MP.US) rose over 8% after receiving funding from the Department of Defense for rare earth projects [4] - Chime (CHYM.US) saw a 37% increase on its IPO day, signaling a revival in the fintech IPO market [4]